Abstract |
131I-Zn(II)-phthalocyanine (ZnPc) incorporated into unilamellar liposomes has been systemically injected to mice bearing a transplanted MS-2 fibrosarcoma. Biodistribution studies show that the pharmacokinetic behaviour of 131I-ZnPc is very similar to that defined for the parent molecule ZnPc including a serum half-life of ca. 12 h, a high recovery from liver and spleen and minimal accumulation in kidney and brain. The most important pharmacokinetic parameter is represented by the high tumour/ muscle ratio of 131I-ZnPc concentration (ca. 9 at 24 h post-injection). These results suggest the possible use of the radiolabelled derivative for a real-time non-invasive monitoring of the ZnPc concentration in the tumour and peritumoural tissue during photodynamic therapy.
|
Authors | L Polo, A Segalla, G Jori, G Bocchiotti, G Verna, R Franceschini, R Mosca, P G De Filippi |
Journal | Cancer letters
(Cancer Lett)
Vol. 109
Issue 1-2
Pg. 57-61
(Dec 03 1996)
ISSN: 0304-3835 [Print] Ireland |
PMID | 9020903
(Publication Type: Journal Article)
|
Chemical References |
- Indoles
- Iodine Radioisotopes
- Isoindoles
- Liposomes
- Organometallic Compounds
- Zinc Compounds
- Zn(II)-phthalocyanine
|
Topics |
- Animals
- Fibrosarcoma
(diagnostic imaging, metabolism)
- Indoles
(pharmacokinetics)
- Iodine Radioisotopes
(pharmacokinetics)
- Isoindoles
- Liposomes
- Mice
- Mice, Inbred BALB C
- Muscles
(metabolism)
- Organometallic Compounds
(pharmacokinetics)
- Radionuclide Imaging
- Time Factors
- Tissue Distribution
- Tumor Cells, Cultured
- Zinc Compounds
|